Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Biology of FasL.

Lee HO, Ferguson TA.

Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):325-35. Review.

PMID:
12787569
[PubMed - indexed for MEDLINE]
2.

Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology.

Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N.

Semin Immunol. 2003 Jun;15(3):167-76. Review.

PMID:
14563115
[PubMed - indexed for MEDLINE]
3.

The role of Fas/FasL interactions in the regulation of B cell function.

Jacobson BA, Rothstein TL, Marshak-Rothstein A.

Behring Inst Mitt. 1996 Oct;(97):185-99. Review.

PMID:
8950476
[PubMed - indexed for MEDLINE]
4.

CD95 (APO-1/Fas) and its ligand in the mouse immune system.

Mariani SM, Matiba B, Krammer PH.

Behring Inst Mitt. 1996 Oct;(97):12-23. Review. No abstract available.

PMID:
8950464
[PubMed - indexed for MEDLINE]
5.

Termination of antigen-specific immunity by CD95 ligand (Fas ligand) and IL-10.

Barreiro R, Luker G, Herndon J, Ferguson TA.

J Immunol. 2004 Aug 1;173(3):1519-25.

PMID:
15265879
[PubMed - indexed for MEDLINE]
Free Article
6.

Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.

Ryan AE, Shanahan F, O'Connell J, Houston AM.

Cancer Res. 2005 Nov 1;65(21):9817-23.

PMID:
16267003
[PubMed - indexed for MEDLINE]
Free Article
7.

Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.

Modiano JF, Sun J, Lang J, Vacano G, Patterson D, Chan D, Franzusoff A, Gianani R, Meech SJ, Duke R, Bellgrau D.

Clin Immunol. 2004 Jul;112(1):54-65.

PMID:
15207782
[PubMed - indexed for MEDLINE]
8.

Fas ligand is localized to membrane rafts, where it displays increased cell death-inducing activity.

Cahuzac N, Baum W, Kirkin V, Conchonaud F, Wawrezinieck L, Marguet D, Janssen O, Zörnig M, Hueber AO.

Blood. 2006 Mar 15;107(6):2384-91. Epub 2005 Nov 10.

PMID:
16282344
[PubMed - indexed for MEDLINE]
Free Article
9.

A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome.

Del-Rey M, Ruiz-Contreras J, Bosque A, Calleja S, Gomez-Rial J, Roldan E, Morales P, Serrano A, Anel A, Paz-Artal E, Allende LM.

Blood. 2006 Aug 15;108(4):1306-12. Epub 2006 Apr 20.

PMID:
16627752
[PubMed - indexed for MEDLINE]
Free Article
10.

Die and let live: eliminating dangerous lymphocytes.

Abbas AK.

Cell. 1996 Mar 8;84(5):655-7. Review. No abstract available.

PMID:
8625402
[PubMed - indexed for MEDLINE]
Free Article
11.

B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.

Bonardelle D, Benihoud K, Kiger N, Bobé P.

J Leukoc Biol. 2005 Nov;78(5):1052-9. Epub 2005 Oct 4.

PMID:
16204618
[PubMed - indexed for MEDLINE]
Free Article
12.

Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies.

Simon AK, Gallimore A, Jones E, Sawitzki B, Cerundolo V, Screaton GR.

Cancer Cell. 2002 Oct;2(4):315-22.

PMID:
12398895
[PubMed - indexed for MEDLINE]
Free Article
13.

Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer.

Shimizu M, Yoshimoto T, Matsuzawa A, Takeda Y.

Mol Biotechnol. 2003 Sep;25(1):79-87.

PMID:
13679638
[PubMed - indexed for MEDLINE]
14.

The role of Fas ligand in immune privilege.

Green DR, Ferguson TA.

Nat Rev Mol Cell Biol. 2001 Dec;2(12):917-24. Review.

PMID:
11733771
[PubMed - indexed for MEDLINE]
15.

Oral nickel tolerance: Fas ligand-expressing invariant NK T cells promote tolerance induction by eliciting apoptotic death of antigen-carrying, effete B cells.

Nowak M, Kopp F, Roelofs-Haarhuis K, Wu X, Gleichmann E.

J Immunol. 2006 Apr 15;176(8):4581-9.

PMID:
16585548
[PubMed - indexed for MEDLINE]
Free Article
16.

Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model.

Fingleton B, Carter KJ, Matrisian LM.

Cancer Res. 2007 May 15;67(10):4800-6.

PMID:
17510409
[PubMed - indexed for MEDLINE]
Free Article
17.

Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system.

Li-Weber M, Krammer PH.

Semin Immunol. 2003 Jun;15(3):145-57. Review.

PMID:
14563113
[PubMed - indexed for MEDLINE]
18.

CD95L/FasL and TRAIL in tumour surveillance and cancer therapy.

Wajant H.

Cancer Treat Res. 2006;130:141-65. Review.

PMID:
16610707
[PubMed - indexed for MEDLINE]
19.

Induction of tolerance using Fas ligand: a double-edged immunomodulator.

Askenasy N, Yolcu ES, Yaniv I, Shirwan H.

Blood. 2005 Feb 15;105(4):1396-404. Epub 2004 Oct 14. Review.

PMID:
15486063
[PubMed - indexed for MEDLINE]
Free Article
20.

Posttranscriptional regulation of Fas (CD95) ligand killing activity by lipid rafts.

Nachbur U, Kassahn D, Yousefi S, Legler DF, Brunner T.

Blood. 2006 Apr 1;107(7):2790-6. Epub 2005 Dec 6.

PMID:
16332972
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk